BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense turns negative

Q3 FY2026 income tax expense was -$8.94B, compared with $4.42M a year earlier. Trailing-twelve-month income tax expense was -$8.87B. Over 3 fiscal years it compounded at +155.4% a year.

Context

  • Income tax expense amounted to 4.1% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Income tax expense increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -$8.94B or moves back toward the trailing-twelve-month quarterly average of -$2.22B.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$8.94B-53872.1% QoQ
Last fiscal yearDec 2025
$133.58M+16.3% YoY
LTMSep 2026
-$8.87B-5681.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-202317.2%——
1 year+16.3%——
3-year CAGR+155.4%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
133.58M USD
Year-over-year change
+16.3%

Income Tax Expense vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -5681.4% is the 10th highest of 11, against a peer median of +17.8%.
  • Income tax expense amounts to 0.9% of revenue for BMRN, versus a peer median of 0.9%.
BMRN Competitors
Income Tax Expense for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026$783.2M USD+1.2%-8.8%6.0%
PHARPharming Group N.V.LTM Mar 2026$7.7M USD-27.6%+98.9%2.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$6.49M USD+129940.0%+46.7%1.0%
INSMInsmed IncorporatedLTM Jun 2026$6.21M USD+39.9%+53.7%0.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$3.82M USD+55.8%-11.1%0.6%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$187K USD+92.1%-56.0%0.0%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-$1.55M USD-147.5%—0.2%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$28.69M USD-177.7%—2.8%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026-$39.75M USD+34.3%+31.2%0.8%
ASNDAscendis Pharma A/SLTM Sep 2026-€619.19M EUR-6542.6%+40.1%51.2%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-$8.87B USD-5681.4%+155.4%0.9%
Peer median (excluding BMRN) —+17.8%+35.6%0.9%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.85B2.1B2.42B2.85B3.22B
Cost of Revenue470.52M503.02M532.06M580.24M736.83M
Gross Profit1.38B1.59B1.89B2.27B2.48B
Gross Margin74.5%76.0%78.0%79.7%77.1%
Research & Development628.79M649.61M746.77M747.18M921.93M
Selling, General & Admin759.4M823.2M892.4M1.01B1.28B
Operating Expenses1.46B1.43B1.7B1.79B1.95B
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
EBITDA47.43M265.36M306.77M650.53M572.94M
EBITDA Margin2.6%12.7%12.7%22.8%17.8%
Operating Income(82.34M)160.97M185.77M484.21M533.48M
Operating Margin-4.5%7.7%7.7%17.0%16.6%
Interest Income10.48M18.03M58.34M74.88M74.9M
Interest Expense15.34M15.97M17.34M12.67M10.9M
Other Income / Expenses6.99M(11.4M)2.79M57.55M(51M)
Income Before Tax(75.35M)149.58M188.56M541.76M482.48M
Pre-Tax Margin-4.1%7.1%7.8%19.0%15.0%
Income Tax Expense(11.27M)8.02M20.92M114.9M133.58M
Net Income(64.08M)141.56M167.65M426.86M348.9M
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (Basic)(0.35)0.760.892.251.82
EPS (Diluted)(0.35)0.750.882.211.80
Weighted Avg Shares182.85M185.27M187.83M190.03M191.79M
Weighted Avg Shares (Diluted)182.85M188.96M191.6M196.71M197.39M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.